Francesca Veronesi

Dr. Francesca Veronesi

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2021 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
FSFrancesca Salamanna
Francesca Salamanna
FVFrancesca Veronesi
Francesca Veronesi
LMLucia Martini
Lucia Martini
MLMaria Paola Landini
Maria Paola Landini
MFMilena Fini
Milena Fini
Whilst the entire world is battling the second wave of COVID-19, a substantial proportion of patients who have suffered from the condition in the past months are reporting symptoms that last for months after recovery, i. e., long-term COVID-19 symptoms. We aimed to assess the current evidence on the long-term symptoms in COVID-19 patients. We did a systematic review on PubMed, Web of Science, EMBASE, and Google Scholar from database inception to February 15, 2021, for studies on long-term COVID-19 symptoms. We included all type of papers that reported at least one long-term COVID-19 symptom. We screened studies using a standardized data collection form and pooled data from published studies. Cohort cross-sectional, case-report, cases-series, case-control studies, and review were graded using specific quality assessment tools. Of 11,361 publications found following our initial search we assessed 218 full-text articles, of which 145 met all selection criteria. We found that 20.70% of reports on long-term COVID-19 symptoms were on abnormal lung functions, 24.13% on neurologic complaints and olfactory dysfunctions, and 55.17% on specific widespread symptoms, mainly chronic fatigue, and pain. Despite the relatively high heterogeneity of the reviewed studies, our findings highlighted that a noteworthy proportion of patients who have suffered from SARS-CoV-2 infection present a “post-COVID syndrome.” The multifaceted understanding of all aspects of the COVID-19 pandemic, including these long-term symptoms, will allow us to respond to all the global health challenges, thus paving the way to a stronger public health.

29 January 2013 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
GDGiovanna Desando
Giovanna Desando
CCCarola Cavallo
Carola Cavallo
FSFederica Sartoni
Federica Sartoni
LMLucia Martini
Lucia Martini
APAnnapaola Parrilli
Annapaola Parrilli
Brunella GrigoloBrunella Grigolo
Brunella Grigolo
Introduction: Cell therapy is a rapidly growing area of research for the treatment of osteoarthritis (OA). This work is aimed to investigate the efficacy of intra-articular adipose-derived stromal cell (ASC) injection in the healing process on cartilage, synovial membrane and menisci in an experimental rabbit model. Methods: The induction of OA was performed surgically through bilateral anterior cruciate ligament transection (ACLT) to achieve eight weeks from ACLT a mild grade of OA. A total of 2 × 106 and 6 × 106 autologous ASCs isolated from inguinal fat, expanded in vitro and suspended in 4% rabbit serum albumin (RSA) were delivered in the hind limbs; 4% RSA was used as the control. Local bio-distribution of the cells was verified by injecting chloro-methyl-benzamido-1,1'-dioctadecyl-3,3,3'3'-tetra-methyl-indo-carbocyanine per-chlorate (CM-Dil) labeled ASCs in the hind limbs. Cartilage and synovial histological sections were scored by Laverty's scoring system to assess the severity of the pathology. Protein expression of some extracellular matrix molecules (collagen I and II), catabolic (metalloproteinase-1 and -3) and inflammatory (tumor necrosis factor- α) markers were detected by immunohistochemistry. Assessments were carried out at 16 and 24 weeks. Results: Labeled-ASCs were detected unexpectedly in the synovial membrane and medial meniscus but not in cartilage tissue at 3 and 20 days from ASC-treatment. Intra-articular ASC administration decreases OA progression and exerts a healing contribution in the treated animals in comparison to OA and 4% RSA groups. Conclusions: Our data reveal a healing capacity of ASCs in promoting cartilage and menisci repair and attenuating inflammatory events in synovial membrane inhibiting OA progression. On the basis of the local bio-distribution findings, the benefits obtained by ASC treatment could be due to a trophic mechanism of action by the release of growth factors and cytokines.

2 October 2012 in Stem Cells and Development
Verified
Journal Article
Closed access
FVFrancesca Veronesi
Francesca Veronesi
Gianluca GiavaresiGianluca Giavaresi
Gianluca Giavaresi
Matilde TschonMatilde Tschon
Matilde Tschon
VBVeronica Borsari
Veronica Borsari
NANicolò Nicoli Aldini
Nicolò Nicoli Aldini
Milena FiniMilena Fini
Milena Fini
Mesenchymal stem cells (MSCs) from bone marrow (BM) are widely used for bone and less for cartilage tissue regeneration due to their self-renewal and differentiating properties into osteogenic or chondrogenic lineages. This review considers the last decade of clinical trials involving a two-step procedure, by expanding in vitro MSCs from BM, or the so called “one-step” procedure, using BM in toto or BM concentrate, for the regeneration of cartilage and osteochondral tissue defects. The following conclusions were drawn: (1) Cartilage defects that can be repaired by the two-step technique are about twice the size as those where the one-step method is used; (2) the two-step procedure is especially used for the treatment of osteoarthritic lesions, whereas the one-step procedure is used for osteochondral defects; (3) the number of transplanted cells ranges between 3.8×10 6 and 11.2×10 6 cells/mL, and the period of cell culture expansion of implanted MSCs varies widely with regard to the two-step procedure; (4) hyaluronic or collagenic scaffolds are used in all the clinical studies analyzed for both techniques; (5) the follow-up of the two-step procedure is longer than that of the one-step method, despite having a lower number of patients; and, finally, (6) the mean age of the patients (about 39 years old) is similar in both procedures. Clinical results underline the safety and good and encouraging outcomes for the use of MSCs in clinics. Although more standardized procedures are required, the length of follow-up and the number of patients observed should be augmented, and the design of trials should be implemented to achieve evidence-based results.

7 August 2013 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
FVFrancesca Veronesi
Francesca Veronesi
Melania MaglioMelania Maglio
Melania Maglio
Matilde TschonMatilde Tschon
Matilde Tschon
NANicolò Nicoli Aldini
Nicolò Nicoli Aldini
Milena FiniMilena Fini
Milena Fini

29 December 2012 in AGE
Verified
Journal Article
Closed access
PDF file
PTP. Torricelli
P. Torricelli
FVFrancesca Veronesi
Francesca Veronesi
SPStefania Pagani
Stefania Pagani
NMN. Maffulli
N. Maffulli
Masiero StefanoMasiero Stefano
Masiero Stefano
Milena FiniMilena Fini
Milena Fini

24 July 2020 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
VCValeria Carina
Valeria Carina
EBElena Della Bella
Elena Della Bella
VCVIVIANA COSTA
VIVIANA COSTA
Daniele BellaviaDaniele Bellavia
Daniele Bellavia
FVFrancesca Veronesi
Francesca Veronesi
Gianluca GiavaresiGianluca Giavaresi
Gianluca Giavaresi